Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy
Annukka A.R. Antar, Katharine M. Jenike, Sunyoung Jang, Danielle N. Rigau, Daniel B. Reeves, Rebecca Hoh, Melissa R. Krone, Jeanne C. Keruly, Richard D. Moore, Joshua T. Schiffer, Bareng A.S. Nonyane, Frederick M. Hecht, Steven G. Deeks, Janet D. Siliciano, Ya-Chi Ho, Robert F. Siliciano
Annukka A.R. Antar, Katharine M. Jenike, Sunyoung Jang, Danielle N. Rigau, Daniel B. Reeves, Rebecca Hoh, Melissa R. Krone, Jeanne C. Keruly, Richard D. Moore, Joshua T. Schiffer, Bareng A.S. Nonyane, Frederick M. Hecht, Steven G. Deeks, Janet D. Siliciano, Ya-Chi Ho, Robert F. Siliciano
View: Text | PDF
Research Article AIDS/HIV

Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy

  • Text
  • PDF
Abstract

Proliferation of CD4+ T cells harboring HIV-1 proviruses is a major contributor to viral persistence in people on antiretroviral therapy (ART). To determine whether differential rates of clonal proliferation or HIV-1–specific cytotoxic T lymphocyte (CTL) pressure shape the provirus landscape, we performed an intact proviral DNA assay (IPDA) and obtained 661 near–full-length provirus sequences from 8 individuals with suppressed viral loads on ART at time points 7 years apart. We observed slow decay of intact proviruses but no changes in the proportions of various types of defective proviruses. The proportion of intact proviruses in expanded clones was similar to that of defective proviruses in clones. Intact proviruses observed in clones did not have more escaped CTL epitopes than intact proviruses observed as singlets. Concordantly, total proviruses at later time points or observed in clones were not enriched in escaped or unrecognized epitopes. Three individuals with natural control of HIV-1 infection (controllers) on ART, included because controllers have strong HIV-1–specific CTL responses, had a smaller proportion of intact proviruses but a distribution of defective provirus types and escaped or unrecognized epitopes similar to that of the other individuals. This work suggests that CTL selection does not significantly check clonal proliferation of infected cells or greatly alter the provirus landscape in people on ART.

Authors

Annukka A.R. Antar, Katharine M. Jenike, Sunyoung Jang, Danielle N. Rigau, Daniel B. Reeves, Rebecca Hoh, Melissa R. Krone, Jeanne C. Keruly, Richard D. Moore, Joshua T. Schiffer, Bareng A.S. Nonyane, Frederick M. Hecht, Steven G. Deeks, Janet D. Siliciano, Ya-Chi Ho, Robert F. Siliciano

×

Figure 9

Persistence of defective HIV-1 proviruses in controllers on ART is similar to that of chronic progressors on ART.

Options: View larger image (or click on image) Download as PowerPoint
Persistence of defective HIV-1 proviruses in controllers on ART is simil...
(A) Summary of provirus types obtained from all time points of the chronic progressors (left) and controllers (right) maintained on long-term suppressive ART. (B) Percentage of various types of defective proviruses relative to total sampled proviruses from 5 chronic progressors (left) and 3 controllers (right), with mean and SEM shown in black. Only 4 categories are shown because only these types are present in all 3 controllers. (C and D) Plots of the percentage of defective proviruses at each participant time point for chronic progressors (left) and controllers (right) on ART by near-full-length sequencing (C) and by IPDA (D). Two-tailed t test P values shown. (E) Summary pie charts of Gag, Pol, and Nef epitope sequences from predicted dominant epitopes from proviruses isolated from chronic progressors and controllers. (F) Percentage of indicated epitope type relative to total epitope sequences at each of 75 (CP, left) or 50 (Ctrl, right) predicted dominant epitopes from 5 CPs and 3 Ctrls, with the mean shown in black. (B and F) No significant differences were observed when the nonparametric Kruskal-Wallis test was applied. (G) Summary pie charts of Gag, Pol, and Nef epitope sequences from Ctrls at time point 1 (T1) and T2/3. E–G share a figure legend. CPs, chronic progressors; Ctrls, controllers; INT, intact; PD, deletion in packaging signal or major splice donor site; LD, deletion of more than 75% of HIV-1 genome length; HM, hypermutated; FL, full-length; FS, intact provirus save for 1 frameshift (A) or preceding frameshift mutation (E–G); INV, deleted with inverted sequence; Del, deleted; SC, preceding stop codon; NFL, near full-length; IPDA, intact proviral DNA assay.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts